Abstract
The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
Original language | English |
---|---|
Pages (from-to) | 1178-1182 |
Journal | Annals of the Rheumatic Diseases |
Volume | 74 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2015 |
Subject classification (UKÄ)
- Clinical Medicine